CA-MARY-KAY
6.11.2020 15:09:07 CET | Business Wire | Press release
Glamhive announced its third online conference to be held on November 14. The Glamhive Digital Fall Style and Beauty Summit will bring together top fashion and beauty leaders, from Sarah Jessica Parker's stylist to Kim Kardashian's hairstylist. The innovative leaders will discuss all things fashion, wellness, beauty, and more. Stephanie Sprangers and Jennifer Rade will co-host the event.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201106005072/en/
"I'm excited to co-host the Glamhive LIVE Fall Style and Beauty summit with Stephanie. We're bringing together the most amazing stylists, makeup artists, hairstylists, designers, & entrepreneurs in the world to share everything we've learned—from how we got started to all our tips and tricks on how to have great personal style," said Jennifer Rade, celebrity stylist and costume designer. Jennifer is one of the busiest stylists working today. Her clientele has ranged from A-List stars Angelina Jolie, Abbie Cornish, Cher, and Jenna Fischer, to musicians Lady A, Pink, Marilyn Manson, Dave Matthews, Amy Winehouse, Motley Crue, and Tina Turner. Her work has been featured in many publications, including W, Vanity Fair, Marie Claire, GQ, Esquire, and Harper's Bazaar.
"Glamhive's vision is to make personal styling available to everyone, everywhere, and our digital events are a wonderful extension of that. This year has enabled us to bring our events to everyone, everywhere so that people who are fashion and beauty enthusiasts or work in the industry can learn from the best in the business," said Stephanie Sprangers, Glamhive founder. Sprangers is the Founder and Chief Executive Officer of Glamhive, the online personal styling service that brings expert personal stylists and makeup artists—recruited directly from Hollywood and Instagram—to everyone. Glamhive has developed proprietary software that allows stylists to take clients through a styling experience that is 100% online, allowing people to work with stylists anywhere in the world.
The all-day, ticketed event will feature 22 segments with 50-plus speakers. Below is an overview of some of the topics that will be covered by their all-star speaker line-up.
TOPICS:
- Zoom Style: Having Great (and Comfortable) Style
- The Making of a Fashion Stylist
- Foundations First
- How Your Home Environment Impacts Your Mood and Reflects Your Style
- How to Build the Wardrobe of Your Dreams
- 360 Style -- The Interplay of Hair, Makeup, and Wardrobe
- Entrepreneurship -- The Courage to Go For Your Dreams
- Future of the Red Carpet
- French Girl Chic and Our Obsession with Emily in Paris
- Shape Matters -- Love Yourself and Your Shape
- Style Your Health - Boosting Your Energy and Immunity
- Skincare Basics: Coaching Clients on Self-Care
- Iconic Style + How to Make a Statement with Your Style
SPEAKERS:
Speakers include celebrity stylists, makeup artists, image-makers who work with the biggest names in Hollywood and beyond, including:
Angelina Jolie, Mandy Moore, Sarah Jessica Parker, Kristen Bell, Khloe Kardashian, Robert Downey Jr, Keanu Reeves, Dwayne Johnson, Donald Glover, Sharon Stone, Serena Williams, Miranda Lambert, Julianne Moore, Liv Tyler, and more.
CELEBRITY STYLISTS:
Jennifer Rade, Ilaria Urbinati, Erin Walsh, Nicole Chavez, Jeanne Yang, Janelle Miller, Lindsey Dupuis, Tiffany Gifford, Sonia Young, Rachel Wirkus, Kesha McCloud
CELEBRITY MAKEUP ARTISTS + HAIRSTYLISTS:
Danesa Myricks, Andrew Fitzsimons, Daniel Martin, Colleen, Runne, Quinn Murphy, Sheridan Ward, Simedar Jackson, and Mia Santiago
ENTREPRENEURS, DESIGNERS, AND BUSINESS LEADERS
Cindy Eckhert (The Pink Ceiling Fund), Jonathan Sposato (Founder, PicMonkey), Carrie Colbert (Curated Capital), Summer Holl (President, Elyse Walker), Christian Juul Nielsen (Herve Leger | Aknvas), Lucy Aylen (Never Fully Dressed), Dr. Shrereene Idress, Dr. Avanti Kumar Singh
MODERATORS:
Brian Underwood (O the Oprah Magazine), Brooke Jaffe (former Fashion Director, Bloomingdales), Jack Eustace, Nicole Young (E! News), Kibwe Chase Marshall, Co-Founder, The Kelly Initiative), Jezlan Moyet.
Tickets to the conference are $99 for an all-day ticket and include a custom playlist by She-J Nikki Pennie. The presenting sponsor for the Glamhive Digital Fall Style and Beauty Summit is Mary Kay and its Mary Kay Global Design Studio. Other sponsors include NuBra USA, LEO, AKNVAS, NYDJ and more.
For more information, visit www.glamhive.com/upcoming .
About Glamhive
Glamhive was founded by entrepreneur Stephanie Sprangers in 2017 with the vision to democratize personal styling and the premise that the confidence that comes with glamour should not be exclusive to the rich and famous.
The online styling experience offers anyone with a WiFi connection access to stylists who will provide them with the support they need to be the best version of themselves. For stylists, it is a seamless end-to-end platform to help them grow their network and their business, 100% virtually.
About Mary Kay
One of the original glass ceiling breakers, Mary Kay Ash founded her beauty company more than 56 years ago with three goals: develop rewarding opportunities for women, offer irresistible products, and make the world a better place. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skin care, color cosmetics, nutritional supplements and fragrances. Mary Kay is committed to empowering women and their families by partnering with organizations from around the world, focusing on supporting cancer research, protecting survivors from domestic abuse, beautifying our communities, and encouraging children to follow their dreams. Mary Kay Ash’s original vision continues to shine—one lipstick at a time. Learn more at MaryKay.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201106005072/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
